menu
    • menu

    Company profile for MimiVax

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Comprehensive Cancer Center that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Ou...
    MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Comprehensive Cancer Center that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Our therapies are designed to stimulate immune responses to control tumor growth and recurrence.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MimiVaxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Elm &, Carlton St, Buffalo, NY 14263
    Telephone
    Telephone
    +1 716-845-8850
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mimivax.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mimivax-llc/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/mimivaxllc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UI Pharmaceuticals Partners with MimiVax for Glioblastoma Vaccine
    UI Pharmaceuticals Partners with MimiVax for Glioblastoma Vaccine

    30 Jun 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/ui-pharmaceuticals-partners-with-mimivax-for-glioblastoma-vaccine/

    CONTRACTPHARMA
    30 Jun 2025
    Share Share
    Keystone Folding Box Co., Med-Con Technologies Enhance Key-Pak
    Keystone Folding Box Co., Med-Con Technologies Enhance Key-Pak

    30 Jun 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/keystone-folding-box-co-med-con-technologies-partner-to-enhance-key-pak/

    CONTRACTPHARMA
    30 Jun 2025
    Share Share
    MimiVax Announces Positive Interim Analysis For SurVaxM Trial
    MimiVax Announces Positive Interim Analysis For SurVaxM Trial

    12 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mimivax-announces-positive-interim-analysis-in-ongoing-survaxm-clinical-trial-302375249.html

    PR NEWSWIRE
    12 Feb 2025
    Share Share
    MimiVax & UI Pharma Achieve Milestone in SurVaxM Production
    MimiVax & UI Pharma Achieve Milestone in SurVaxM Production

    10 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mimivax-and-ui-pharmaceuticals-achieve-milestone-in-survaxm-production-for-glioblastoma-treatment-302347640.html

    PR NEWSWIRE
    10 Jan 2025
    Share Share
    FDA Grants Orphan Status To SurVaxM For Malignant Glioma Treatment
    FDA Grants Orphan Status To SurVaxM For Malignant Glioma Treatment

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-awards-supplemental-orphan-drug-designation-to-survaxm-to-now-include-treatment-of-malignant-glioma-302158604.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    MimiVax Announces New Investments to Support Clinical Development of SurVaxM
    MimiVax Announces New Investments to Support Clinical Development of SurVaxM

    09 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mimivax-announces-new-investments-to-support-clinical-development-of-survaxm-in-glioblastoma-302029983.html

    PR NEWSWIRE
    09 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search